While fundamentals show increased losses, the substantial cash improvement and non-dilutive funding reduce near-term dilution risk. Multiple 2026 clinical catalysts (ARDS, GVHD, IPF) could drive value inflection; traders should monitor trial initiations and data readouts as key triggers.
Price Chart
Executive Summary
MiNK Therapeutics reported financial results for Q4 and full year 2025, highlighting a net loss increase to $12.5M but improved cash position of $13.4M, supported by non-dilutive funding and a recent $3M raise. The company emphasized pipeline progress, including upcoming Phase 2 trials in ARDS and GVHD, with multiple clinical catalysts expected in 2026.
Key Financial Metrics
Key Facts
- Net loss for FY 2025 was $12.5 million, up from $10.8 million in 2024.
- Cash and cash equivalents totaled $13.36 million as of December 31, 2025, up from $4.58 million in 2024.
- Raised additional $3.0 million post-year-end via at-the-market offering, extending cash runway into 2026.
- Phase 2 trial for agenT-797 in ARDS to initiate in 1H 2026, with early data expected by year-end.
- GVHD program fully funded by NIH grant and philanthropic award, with first dosing expected May 2026.
- C-Further Consortium collaboration provides up to $1.1 million in non-dilutive funding plus revenue share for PRAME-TCR iNKT program.
Financial Impact
Net loss increased 15.7% YoY to $12.5M; cash position improved by $8.78M; $3M raised post-period; $1.1M non-dilutive funding secured.
Risk Factors
- Continued net losses may pressure valuation if clinical milestones are delayed.
- Reliance on external funding for GVHD program creates execution risk if trial timelines slip.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265350 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access